Autolus Therapeutics to report Q1 2026 financial results on May 14 with a conference call.

Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, will release its first quarter 2026 financial results and operational highlights on May 14, 2026, before U.S. markets open. The company will host a conference call and webcast at 8:30am EDT to discuss the results and provide a business update. Autolus is known for its marketed therapy AUCATZYL® and is developing treatments for cancer and autoimmune diseases. This report will give investors insight into the company’s recent performance and strategic direction.